Lipoarabinomannan glycoconjugate derivatives in active and passive protection against tuberculosis
- 1University of Minho, Portugal
- 2Department of Medicine, Solna, Karolinska Institutet, Sweden
- 3University of Leicester, United Kingdom
- 4Karolinska Institute (KI), Sweden
Glycolipids of the cell wall of Mycobacterium tuberculosis (Mtb) are important immunomodulators in tuberculosis. In particular lipoarabinomannan (LAM) has a profound effect on the innate immune response. LAM and its structural variants can be recognized by and activate human CD1b restricted T cells, and emerging evidence indicates that B cells and antibody against LAM can modulate the immune response to Mtb. Anti-LAM antibodies are induced during Mtb infection and after BCG vaccination, and monoclonal antibodies against LAM have been shown to confer protection by passive administration in mice and guinea pigs. In this review we describe the immune response against LAM and the potential use of the mannose-capped arabinan moiety of LAM in the construction of vaccine candidates against tuberculosis.
Keywords: Lipoarabinomannan, Tuberculosis, Mycobacterium, glycolipid, Antibodies, monoclonal, Vaccine, immune response
Received: 06 Jun 2019;
Accepted: 05 Aug 2019.
Copyright: © 2019 Correia-Neves, Sundling, Cooper and Källenius. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Prof. Gunilla Källenius, Karolinska Institute (KI), Solna, Sweden, email@example.com